Lyell Immunopharma completed its initial public offering (IPO) on the Nasdaq global select market, pricing its shares at $17.00 per share. The offering successfully raised substantial capital to fund its early-stage research platforms, cellular reprogramming technologies, and clinical pipeline development for cancer immunotherapies. Like many clinical-stage biotechnology equities, the share price has experienced significant post-IPO volatility driven by broader market shifts, macroeconomic pressures, and pipeline milestones, trading well below its initial public offering value as the firm matures its therapeutic pipeline.